Medical professionals should prioritize the administration of SGLT2 inhibitors for patients with HF and T2D, as well as specifically utilize dapagliflozin or empagliflozin in patients with HFrEF to enhance cardiovascular outcomes, reduce hospitalizations for HF, and lower all-cause mortality. The gene discussed is SLC5A2; the disease is hydrops fetalis.